Purpose: To evaluate the efficacy of radiotherapy (RT) with total dose of 20 Gy (RT 20 Gy) in the treatment of Graves' ophthalmopathy. Methods: A systematic review and metaanalysis of randomized controlled trials was performed comparing RT 20 Gy with or without glucocorticoid to cli nical treatments for Graves' ophthalmopathy. The MEDLINE, EMBASE, Cochrane Library databases and recent relevant journals were searched. Relevant reports were reviewed by two reviewers. Response to radiotherapy was defined as clinical success according to each trial. We also evaluated the quality of life and whether RT to produce fewer side effects than other treatments. Results: A total of 8 randomized controlled trials (439 patients) were identified. In the subgroup analysis, the overall response to treatment rates was better for: RT 20 Gy plus glucocorticoid vs glucocorticoids alone, OR=17.5 (CI95% 1.85250, p=0.04), RT 20 Gy vs sham RT, OR= 3.15 (CI95%1.596.23, p=0.003) and RT 20Gy plus intravenous glucocorticoid vs RT 20Gy plus oral glucocorticoid, OR=4.15(CI95% 1.3412.87, p=0.01). There were no differences between RT 20 Gy versus other fractionations and RT 20 Gy versus glucocorticoid alone. RT 20 Gy with or without glucocorticoids showed an improvement in diplopia grade, visual acuity, optic neuropathy, lid width, proptosis and ocular motility. No difference was seen for costs, intraocular pressure and quality of life. Conclusion: Our data have shown that RT 20 Gy should be offered as a valid the rapeutic option to patients with moderate to severe ophthalmopathy. The effecti veness of orbital radiotherapy can be increased by the synergistic interaction with glucocorticoids. Moreover, RT 20 Gy is useful to improve a lot of ocular symptoms, excluding intraocular pressure, without any difference in quality of life and costs.
INTRODUCTION
Graves' ophthalmopathy is a debilitating disease impairing the quality of life of the affected individuals. Despite recent progress in the understanding of its pathogenesis, treatment is often not sa tisfactory. In mild cases, local therapeutic measures (artificial tears and ointments, sunglasses, nocturnal eyes taping, prisms) can con trol symptoms and signs. In severe forms of the disease, aggressive measures are required. The management strategy for moderate to severe Graves' ophthalmopathy is controversial. Systemic steroids are often effective (14) , but relapse is common when they are tapered or withdrawn (5) . A number of retrospective studies have reported the efficacy of orbital irradiation (6, 7) but prospective studies have shown conflicting results (810) . Some investigators have suggested that ste roids provide excellent improvement in orbital inflammation in the short term, whereas the effects of orbital irradiation take longer to appear (11) . Studies that have compared combination therapy of or bi tal irradiation and systemic steroids with steroids alone therapy have produced conflicting results (1218) . The accomplishment of a sys tematic review is the best manner for describing the state of our knowledge, and hence becomes the best way of obtaining high qua lity scientific evidence. Consequently, this systematic review was proposed to analyze the results from clinical trials that compared ra diotherapy to any other treatment. RT 20 Gy contra outros fracionamentos e 20 Gy RT contra glicocorticoides sozinhos. RT 
RESUMO Objetivo: Avaliar a eficácia da radioterapia (RT) com dose total de 20 Gy (RT 20 Gy) no tratamento da oftalmopatia de Graves.

Métodos: Uma revisão sistemática e meta-análise de ensaios clínicos randomizados foram realizadas comparando RT 20 Gy, com ou sem glicocorticoides a tratamentos clinicos para a oftalmopatia de Graves. O MEDLINE, EMBASE, bases de dados da Biblioteca Cochrane e recentes de revistas relevantes foram pesquisados. Relatórios relevantes foram revisados por dois revisores. A resposta à radioterapia foi definida através do sucesso clinico de acordo a cada ensaio clínico. Nós também avaliamos a qualidade de vida e se a radioterapia produzia menos efeitos colaterais comparados a outras intervenções.
Resultados: Um total de 8 ensaios clínicos randomizados (439 pacientes) foram identificados. Na análise de subgrupo, a resposta global para as taxas de tratamento foi melhor para: RT 20 Gy além de glicocorticoides vs glicocorticoides sozinhos, OR=17,5 (IC95% 1,85-250, p=0,04), RT 20 Gy vs sham RT, OR=3,15 (IC95% 1,59-6,23, p=0,003) e RT 20 Gy além de glicocorticoides por via intravenosa RT 20 Gy além de glicocorticoides orais, OR=4,15 (IC95% 1,34-12,87, p=0,01). Não houve diferenças entre
METHODS
Types of sTudies
This systematic review properly included randomized control led clinical trials. Any trial including only patients with mild Graves ophthalmopathy (GO), or any trial including patients with modera tesevere GO were included. The participants of studies included patients with GO diagnosis for the first time, not resistant to previous treatment and with no age limit. The intervention criteria to be in cluded in this review was any trial in which radiotherapy with total dose of 20 Gy associated or not to glucocorticoid (of any kind) was the primary treatment compared to radiotherapy (RT) with total dose different of 20 Gy, no radiotherapy or any another treatment. The efficacy of radiotherapy was evaluated following measures after treatment. The lid width was measured as the widest vertical dimension, proptosis was measured by an exophthalmometer, ocular motion was measured in degrees or constancy of diplopia, intraocu lar pressure measured using an applanation tonometer, optic nerve function was assessed by recording of the corrected visual acuity or fundoscopy. Response to radiotherapy was defined as clinical suc cess according to each trial. We also evaluated the quality of life and whether RT produced fewer side effects than other treatments. Medline and manual searches were done (completed independently and in duplicate) to identify all published (manuscripts and abstracts) randomized controlled trials (RCTs) that compared radiotherapy for GO to any treatment. The Medline search was done between 1966 and 2006 with no language restrictions, using the search terms "ophthalmopathy, " orbitopathy" and "Graves' ophthalmopathy, " "ra diotherapy" or "orbital radiotherapy, " and "retro ocular radiotherapy". The second search was done through EMBASE and the Cochrane Li brary to identify randomized trials published between January 1998 and July 2006, using MeSH headings (ophthalmopathy, orbipathy, Graves' ophthalmopathy, orbital radiotherapy, retro ocular radiothe rapy /sc {Secondary}, exlode Clinical Trials, clinical trial {publication type}) and text words (retro ocular radiotherapy radiotherapy, Graves' ophthalmopathy, trial, and study) without language restrictions. All the searched abstracts were screened for relevance. Manual searches were done by reviewing articles and abstracts cited in the reference lists of identified RCTs, by reviewing the first author's article, abstract file, from reference lists of retrieved papers, textbooks and review articles. Hand searches were carried out in the following journals between January Ophthalmology; Lancet; Ophthalmology; International Journal of Radiation Oncology, Biology, and Physics; and Journal of Clinical endocrinology and metabolism. Reference lists from identified studies and other relevant publications were scrutinized. Colleagues, collaborators, and other experts were contacted about ongoing and unpublished trials. From the titles and abstracts, relevant RCTs were identified. Two independent reviewers (V.A.G., A.C.B.) then assessed the RCTs to establish if predetermined inclusion criteria were met. Study suitableness was assessed using QUOROM criteria (19) . The RCTs were also independently assessed for quality according to predeter mined criteria (method of randomization, blinding, statistical me thods, quality of life assessment, data completeness, followup), and the data extracted and tabulated. Discrepancies between the two reviewers were resolved by discussion. The intention was to carry out a metaanalysis of outcomes if there were enough trials of sufficient quality and homogeneity.
sTaTisTics
The efficacy of radiotherapy treatment with total dose of 20 Gy was measured through the response to treatment described in each trial. Responders to treatment were defined as patients who presen ted overall response to radiotherapy or other treatment, according to clinical success defined according to each trial. The data analyses were made with Review Manager Version 5.1 provided by The Coch rane Collaboration. All analyses were carried out on an intention to treat basis; that is, all patients randomly assigned to a treatment group were included in the analyses according to the assigned treat ment, irrespective of whether they received the treatment or were excluded from analysis by the investigators. For categorical variables, weighted risk ratios and their 95% confidence interval were calcu lated using RevMan 5.1 software according to the Peto method (20) . Results were tested for heterogeneity at significance level of P<0.05 according to the methods outlined by Der Simonian and Laird (21) . A fixed effects model was used if there was no evidence of heterogenei ty between studies, if there was evidence of heterogeneity random effects model was used for metaanalysis.
The odds ratio and 95% confidence interval were calculated for each trial and presented in a Forrest plot. Sensitivity analyses was performed by excluding the trials which Jadadscale was only 1 score. Publication bias is a common concern in metaanalysis that is rela ted to the tendency of journals to favor the publication of large and positive studies. We chose a commonly used method for detecting publication bias, which is a graphical plot of estimates of the ORs from the individual studies versus the inverse of their variances, which is commonly referred to as a "funnel plot. " An asymmetry in the funnel would be expected if there was publication bias with smaller studies tending to show larger ORs, because small studies with no significant statistical results would be less likely to be reported.
RESULTS
sTudy characTerisTics
A total of 359 studies of treatment of GO were identified, from which we excluded those that did not involve the use of RT, thus limiting the selection to 22 studies. Of these only 8 were controlled clinical studies. Fourteen studies were excluded due to lack of origi nal data, insufficient data for analysis, lack of randomization and/or retrospective design, no control group, earlier reports on individual studies. A total of 8 studies were included in this review (810, 1216) , as demonstrated in the figure 1. Study characteristics are shown in ta ble 1. The studies were clearly heterogeneous, so we divided them into six groups:
A. 1 randomized studies (15 patients) that assessed the efficacy and safety of combined orbital irradiation and systemic steroids in the management of moderatetosevere Graves' ophthal mopathy (16) . B. 3 studies (190 patients) tested the efficacy of external beam irradiation compared with shamirradiation (9, 10, 15) . C. 1 study (82 patients) assessed the efficacy and safety of orbital radiotherapy combined with either oral glucocorticoid or iv glucocorticoids (14) . D. 1 study (66 patients) compared the efficacy and tolerability of three RT protocols (12) . E. 1 study (56 patients) evaluated the efficacy of combined the rapy RT plus systemic methylprednisolone or systemic methyl prednisolone alone. F. 1 study (30 patients) compared the efficacy of combined the rapy RT plus systemic glucocorticoids plus and radiotherapy alone (13) . The studies had a randomized design with 209 patients submitted to RT with or without glucocorticoids and 230 patients submitted to other treatment (9, 10, 1216) . The parameters evaluated in these stu dies were: Quality of life, costs, proptosis, visual acuity, diplopia, intraocular pressure, optic neuropathy, ocular motility and clinical response. Seven studies included in this review tested the efficacy of RT 20 Gy to improve proptosis (9, 10, 12, 1416) . However, only in the stu dy performed by Marcocci et al., (14) there was significant difference between the two modalities of treatment. Five studies investigated the lid width (9, 10, 12, 14, 15) again Marcocci et al., (14) was the only study to demonstrate significant difference. The visual acuity was evaluated in three RCTs, (12, 13, 16) only one trial (13) showed benefit for RT 20 Gy arms. Diplopia was assessed in five RCTs (9, 10, 12, 14, 15) of these studies Prummel et al., (15) and Mourits et al. (9) founded significant differences between radiotherapy versus sham radiotherapy for changes in diplopia, in the other studies it was not seen. Intraocular pressure was tested in two RCTs (12, 16) , one performed by Ng et al. (16) , and another by Kahaly et al. (12) , in both studies no benefit was seen in combined orbital irradiation and systemic steroids or using low dose of radiotherapy. Mar cocci et al. (14) , was the only trial to assess the efficacy of radiothe rapy to improve optic neuropathy. In this study combined orbital irradiation and systemic steroids were associated with significant difference to improve optic neuropathy.
Ocular motility and clinical response was tested in all RCTs (810, 1216) . RT 20 Gy with or without glucocorticoid achieved significant statisti cal difference in five of the eight trials evaluated for clinical response. Ocular motility was improved in six trials (8, 9, 1316) comparing RT 20 Gy with other treatments. Table 2 summarizes the parameters evalua ted and the treatment results. According to the Jadad criteria, we assessed the quality of the randomized and comparative trials with regard to: a) method of randomization, b) treatment allocation, c) similarity between groups, d) specification of eligible criteria, e) blin ded outcome of assessor, care provider and patient (22) . Applying these criteria made clear that the quality of the trials was high, as showed in the table 3 which describes in details the trials design, aim, study question, results, and conclusions.
response To TreaTmenT
All the studies reported response to treatment as one of the out comes. The criterions for evaluation of the response to treatment were heterogeneous between the trials. Altogether, the analyses included 8 trials with 439 patients (9, 10, 1216) . The individual odds ratios ranged from 0.87 to 17.5 with a pooled odds ratio for all of the trials of 2.14 with a 95% confidence interval of 1.44 to 3.18. The test for heterogeneity was not statistically significant with p value 0.14, which indicates that the pooling of the data was valid. The overall odds ratio suggests that there is difference between RT 20 Gy arms and other treatments in terms of response to treatment rate with p value 0.0002, as shown in the figure 2.
radioTherapy versus sham radioTherapy
Three trials (9, 10, 15) with 190 patients evaluated response to treat ment comparing radiotherapy versus sham radiotherapy. The in dividual odds ratios ranged from 1 to 3.5 with a pooled odds ratio for all of the trials of 3.15 with a 95% confidence interval of 1.59 to 6.23. The test for heterogeneity was not statistically significant with p value 0.28, which indicates that the pooling of the data was valid. RT and oral prednisone appear to be equally effective as initial treatment in patients with moderately severe Graves' ophthalmopathy. In view of its better tolerability, radiotherapy should be considered the treatment of first choice
Marcocci et al., 2001
Randomized trial
To assess the efficacy and safety of orbital radiotherapy combined with either oral (prednisone; starting dose, 100 mg/d; withdrawal after 5 months) or IV (methylprednisolone; 15 mg/kg for four cycles and then 7.5mg/kg for four cycles; each cycle consisted of two infusions on alternate days at 2wk intervals) glucocorticoids A significant reduction in proptosis (from 23.2 ± 3.0 to 21.6 ± 1.2 mm in the IV glucocorticoid group, P<0.0001; and from 23 ± 1.8 to 21.7 ± 1.8 mm in oral glucocorticoid group, P <0.0001) and in lid width (from 13.3 ± 2.5 to 11.8 ± 2.2 mm, and from 13.6 ± 2.0 to 11.5 ± 1.9 mm, respectively; P<0.001 in both cases) occurred, with no difference between the two groups. Diplopia significantly improved in both groups: it disappeared in 13 of 27 (48.1%) IV glucocorticoid patients (P<0.005) and in 12 of 33 (36.4%) oral glucocorticoid patients (P<0.03)
Highdose IV glucocorticoid and oral glucocorticoid (associated with orbital radiotherapy) are effective in the management of severe Graves' ophthalmopathy, but the IV route seems to be more effective and better tolerated than the oral route and associated with a lower rate of side effects
Gorman et al., 2001
Prospective, randomized, internally controlled, doubleblind clinical trial
To evaluate the efficacy of radiotherapy for GO No clinically or statistically significant difference between the treated and untreated orbit was observed in any of the main outcome measures at 6 months. At 12 months, muscle volume and proptosis improved slightly more in the orbit that was treated first
This study was unable to demonstrate any beneficial therapeutic effect. The slight improvement noted in both orbits at 12 months may be the result of natural remission or of radiotherapy, but the changes are of marginal clinical significance
Kahaly et al., 2000
To compare the efficacy and tolerability of three Rx protocols.
Response to therapy, defined as a significant amelioration of three objective parameters, was noted in 12 A (67%), 13 B (59%), and 12 C (55%) subjects (C vs. A, P 5 0.007). Ophthalmic symptoms and signs regressed most in group A; changes in lid fissure width were 21.5, 20.5, and 0 mm in the A, B, and C groups, respectively (A vs. C, P<0.005), whereas changes in intraocular pressure (upgaze) were 23, 11, and 21.5 mmHg, respectively (A vs. B, P 5 0.002)
Patients with moderately severe GO, similar response rates were observed for low and high Rx doses, but the 1 Gy/week protocol was more effective and better tolerated than the short arm regimens Bartalena et al., 1983 Randomized trial
To asses the efficacy to either combined therapy or systemic methylprednisolone alone
Patients treated by combined therapy, 12 (33%) showed excellent responses, 14 (39%) showed good responses, 9 (25%) showed slight responses, and 1 (3%) had no response. Treatment was more effective for soft tissue involvement, newly developed ophthalmoplegia, and optic neuropathy, while proptosis and longstanding ophthalmoplegia were less responsive
The study indicates that both orbital RT combined with systemic methylprednisolone treatment and systemic methylprednisolone therapy alone are valuable methods of treatment for Graves' ophthalmopathy, but the combined therapy proved to be more effective 
radioTherapy plus glucocorTicoid versus glucocorTicoid
One randomized study (16) (15 patients) compared the efficacy of combined orbital irradiation and systemic steroids in the manage ment of moderatetosevere Graves' ophthalmopathy. The odds ratio for this trial was of 17.50 with a 95% confidence interval of 1.85 to 250. The test for heterogeneity was not statistically significant with p value 0.42, which indicates that the pooling of the data was valid. The overall odds ratio suggests that there is difference between RT 20 Gy arms and glucocorticoid arms in terms of response to treatment rate with p value 0.04, as demonstrated in the table 4.
radioTherapy plus iv glucocorTicoid versus radioTherapy plus oral glucocorTicoid
One study (14) (82 patients) compared the efficacy radiotherapy plus IV glucocorticoid versus radiotherapy plus oral glucocorticoid. The odds ratio of this study was 4.15 with 95% confidence inter val of 1.34 to 12.87, suggesting that there is difference between radiotherapy plus IV glucocorticoid versus radiotherapy plus oral glucocorticoid in terms of response to treatment with p value 0.01, shown in table 4.
radioTherapy wiTh 20 gy versus oTher fracTionaTions
One study (12) (66 patients) compared the efficacy of radiotherapy with a total dose of 20 Gy versus others fractionations. The odds ratio of this study was 1.10 with 95% confidence interval of 0.39 to 3.10, suggesting that there is no difference between radiotherapy with a total dose of 20 Gy versus others fractionations for response to treat ment, as demonstrated in table 4.
QualiTy of life and cosTs
One study of Prummel et al., (15) (88 patients) evaluated the quality of life and costs and did not evidence differences in quality of life or costs between patients submitted to radiotherapy versus sham radiotherapy for GO.
radioTherapy versus glucocorTicoid
One study (8) (56 patients) compared the efficacy of radiotherapy with a total dose of 20 Gy versus glucocorticoid. The odds ratio of this study was 0.87 with 95% confidence interval of 0.30 to 2.87, suggesting that there is no difference between radiotherapy with a total dose of 20 Gy versus glucocorticoid for response to treatment, as described in table 4.
radioTherapy plus iv glucocorTicoid versus radioTherapy alone
One study (13) (30 patients) compared the efficacy of radiotherapy plus IV glucocorticoid versus radiotherapy alone. The odds ratio this study was 3 with 95% confidence interval of 0.68 to 13.31, suggesting that there is no difference between radiotherapy with a total dose of 20 Gy plus glucocorticoid versus radiotherapy alone for response to treatment, as shown in table 4.
QualiTy of sTudies
The median of the quality scores was of 4 points (in a 5point scale), with none study scoring 0, 1, 2, or 3. There was complete agre ement in scoring by the two assessors. The quality scores were high, five trials scored 5 points (810, 15, 16) and three trials scored 4 points in the Jada scale. This fact occurred because of the importance placed on blinding in the scoring system, and the inherent difficulty in blinding a treatment such as radiation, as shown in the table 3.
evaluaTion of publicaTion bias
The funnel plot of the log ORs versus the inverse of their variances of the individual studies is displayed in figure 3 . The plot formed a very distinct funnel shape with the log ORs evenly distributed around the metaanalysis OR regardless the study variance. Therefore, there was no indication of an asymmetry in the study findings by the variance or size of the studies and, thus, little evidence for publication bias.
DISCUSSION
External radiotherapy has been used for GO for around 60 years and it still represents a mainstay in the management of the disease (23) . The rationale for the use of radiotherapy for GO resides both in its OR: odds ratio. nonspecific antiinflammatory effect and in the high radio sensitivity of lymphocytes infiltrating the orbital space (24) . Lymphocytes are ge nerally suppressed with relatively low doses of radiation, and the hel per/suppressor T lymphocyte ratio is also altered by radiotherapy (23) . In addition, radiotherapy might also reduce glycosaminoglycans production by orbital fibroblasts (25) . Whether the reported effective ness of orbital radiotherapy in GO is related either to its nonspecific antiinflammatory action, or to specific immunosuppressive effects, both need to be clarified. Our review of papers published between 1983 and 2006 showed that positive results were obtained using RT. According to most studies, orbital radiotherapy is especially effective on soft tissue inflammatory changes and recent extraocular muscle involvement, producing improvement in the ocular parameters as visual acuity, diplopia, proptosis, lid width, ocular motility and op tic neuropathy, but without any benefit on intraocular pressure. It should be mentioned that all studies were randomized, controlled and of high quality. The latest 5 years have witnessed important dis cussions on the role of orbital radiotherapy, in particular questioning its effectiveness and safety (2632) .
Most authors agree that orbital radiotherapy is a safe procedure. If the technique of radiation is correct, it seems not to increase the risk of cataract and retinopathy, except for patients with diabetic and hypertensive retinopathy (33, 34) . The two latter conditions, especially if associated, should be considered as relative contraindications to orbital radiotherapy, in particular when signs of retinopathy are present before irradiation. It is worth noting that, even after a very long followup, orbital radiotherapy does not seem to bear a risk of radiationinduced tumors (3540) . Thus, the safety of orbital radiotherapy is not a major matter of argument, but there is a controversy about its real effectiveness. This debate has been revitalized by a randomi zed, placebocontrolled, doubleblind study from the Mayo Clinic (10) . In the original experimental design of this study, only one orbit of 42 patients with moderately severe GO was irradiated, whereas the contralateral orbit served as an internal control. A detailed analysis of objective measures was provided; leading the authors to conclude that orbital radiotherapy is ineffective and therefore, should not be offered to GO patients (10) . Although Gorman et al. should be congra tulated on the major effort they made, our point about this study is that it has some structural errors.
One of them was the fact that a lot of patients had a long stan ding ophthalmopathy and had been already treated before, apparently not well succeeded, by systemic glucocorticoids (10) . The second one involves timing of therapy, and the therapeutic goals of orbital radiation therapy. The authors in their study included pa tients between 0.2 and 16 years, with a median of 1.3 years with onset from the eye symptoms. The authors made no attempt to treat patients in the active progressive phase of thyroid eye disease. This phase disease is characterized by infiltration of the extraocular muscles with lymphocytes, and it is the prime radiation sensitive period. Patients who do not respond to glucocorticoids are unli kely to show any benefit from orbital radiotherapy. In addition, the obser vation that the untreated orbit did not show any improve ment or worsening during the 6months period of further observa tion suggesting that enrolled patients had stable, non progressive, i.e. inactive ("burntout") eye disease. The third vital error was the stated goal of orbital radiation. In many institutions the stated goal of therapy is to halt or reverse severe progressive thyroid ophthal mopathy. The author's therapeutic objectives of treating patients who had chronic fibrotic thyroid ophthalmopathy established were unclear. This article seemed to evaluate if radiation therapy reversed such findings as orbital volume in patients with chronic thyroid ophthalmopathy. Our final concern about this article was the unusual port design for radiation therapy. This design may be useful as a research data, on the other hand, being human studies it can be considered as worrisome. Treating with their wedge pair field design to spare the contralateral eye, the authors increased the volume of normal tissue significantly, including the frontal lobes and parotid glands, exposed to radiation compared to the standard opposed lateral fields. Although the risks of a secondary malignancy in the treatment of those patients are slight, increasing the volume would be expected to increase this risk. But the longterm effects of a low dose radiation in a larger volume of the frontal lobe may have subtle effects in the higher brain functions.
What did the other randomized controlled trials tell us about the efficacy of orbital radiotherapy for GO? In 1993, a randomized doubleblind trial of prednisone vs. orbital radiotherapy in patients with moderately severe GO (8) demonstrated that the proportion of responders in prednisonetreated (14 of 28, 50%) and irradiated (13 of 28, 46%) patients (18%) was similar. That time, there were no doubts that glucocorticoid was an effective treatment for GO. Ho wever, from this study through non direct comparison RT has star ted to be also considered effective. In addition, the study above also demonstrated a decrease in the eye muscle volume, as assessed by the eye muscle score (8) . In 2000 those data were confirmed for a doubleblind ran SE: size effect; OR: odds ratio. domized study which included 60 patients with moderately severe GO who were submitted to either orbital radiotherapy or shamirra diation (9) . The qualitative treatment outcome was successful in 60% of irradiated patients and in only 31% of sham irradiated patients (9) . Improvement was mainly confined to eye movements; it should also be noted that 25% of irradiated patients were saved from additional strabismus surgery (9) . In 2004 a new important information (15) about the use of orbital radiotherapy was provided for GO by Prummel et al. This doubleblind, randomized clinical trial was the first to address the question of whether orbital radiotherapy has a place in the ma nagement of nonsevere GO. Based on the evaluation of changes in major and minor criteria prespecified, primary therapeutic outcome was successful in 52% of irradiated patients and in only 27% of shamir radiated patients (15) , with improvement in the eye muscle function and diplopia. It should also be noted that the orbital radio therapy was not associated with a greater improvement of quality of life, compared to sham irradiation (15) . This paper also provides valua ble information that orbital radiotherapy did not prevent progression to more severe expressions in about 15% of the patients. The reason why the severe forms of GO develop is still un clear nowadays, but it seems that environmental factors play a decisive role in this progres sion (40) . Thus, if the study by Prummel et al. (15) , lends further support to the concept that orbital radiotherapy is in general an effective treatment for GO, it also suggests that the commonly adopted policy of "waitandsee" in cases of mild GO should be maintained, including the cost/benefit considerations. At present, most centers utilize linear accelerators delivering 46 megavolts and use a 4 x 4cm lateral field slightly angled posteriorly to avoid as much as possible irradiation to the contralateral lens. The use of higher energy sources has not proven to be particularly advantageous. The most common delive red dose is 20 grays (Gy) per eye (30) ; this cumulative dose is usually fractionated in 10 daily doses over a 2week period to reduce the cataractogenic effect of irradiation (27) . The importance of dose was evaluated by Kahaly et al., (12) , using different radiation doses. It repor ted that a therapeutic scheme of 1 Gy per week over a 20week period was equally effective and possibly better tolerated than the classi cal 2week scheme. The use of higher cumulative doses of radiation (30 Gy vs. 20 Gy) does not produce any increase in the effectiveness of treatment (41) . Irrespective of small differences observed using lowdose vs. highdose radiotherapy, beneficial effects of radiothe rapy were observed in all the three groups of patients in 55 to 67% of cases. In summary, what is the message to the reader, based on the present systematic review?
CONCLUSION
Our data has shown that orbital radiotherapy still has an impor tant role in the management of GO. Although there are a lot of avai lable studies in the literature, they have a limited impact owing to selection bias and lack of an appropriate ophthalmological assess ment. In the era of evidencebased medicine it cannot be denied that six of eight randomized and controlled studies showed that or bital radiotherapy is effective on GO, especially on extraocular mus cle involvement. Orbital radiotherapy, in burning out eye disease, can also make eye muscle and/or eyelid corrective surgery possible in earlier stages. The effectiveness of orbital radiotherapy can be in creased by the synergistic interaction with glucocorticoids. Orbital radiotherapy should still be offered as a valid therapeutic option to patients with moderate to severe GO. The selection of patients is fundamental, be cause patients with inactive ("burntout") GO are unlikely to respond to irradiation (as well as to glucocorticoids). The use of orbital radiotherapy in the early stage of the disease (possibly less than 1 year from the onset) is recommended. The real efficacy of orbital radiotherapy should come from welldesigned, multicenter, randomized and controlled studies enrolling a large number of patients.
